News Releases

Date Title and Summary Additional Formats
Toggle Summary Avacopan Conditional Marketing Authorization Application Accepted for Regulatory Review by European Medicines Agency
Conditional marketing authorization application for treatment of patients with ANCA-associated vasculitis validated for start of procedure by EMA Significant milestone further strengthens Kidney Health Alliance ChemoCentryx to receive regulatory milestone payment from VFMCRP VIFOR FRESENIUS MEDICAL
View HTML
Toggle Summary ChemoCentryx Achieves $5 Million Milestone from GlaxoSmithKline for Nomination of CCR1 Small Molecule Development Candidate
ChemoCentryx Achieves $5 Million Milestone from GlaxoSmithKline for Nomination of CCR1 Small Molecule Development Candidate Mountain View, CA - July 24, 2007 - ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered
View HTML
Toggle Summary ChemoCentryx Advances a New Generation CCR9 Inhibitor, CCX507, Into Clinical Development
MOUNTAIN VIEW, Calif. , Jan. 7, 2013 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today the initiation of a Phase I clinical trial for CCX507, the Company's novel, wholly-owned inhibitor of the chemokine receptor known as CCR9. The double-blind, placebo-controlled study will
View HTML
Toggle Summary ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 into Clinical Development
Solidifies Company's Leadership Position in Targeting Chemokine Receptor CCR9 for Gastrointestinal Diseases
View HTML
Toggle Summary ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 into Clinical Development
Solidifies Company's Leadership Position in Targeting Chemokine Receptor CCR9 for Gastrointestinal Diseases
View HTML
Toggle Summary ChemoCentryx and Forest Laboratories to Collaborate on The Development and Commercialization of Novel Oral Rheumatoid Arthritis and Multiple Sclerosis Therapeutics
ChemoCentryx and Forest Laboratories to Collaborate on The Development and Commercialization of Novel Oral Rheumatoid Arthritis and Multiple Sclerosis Therapeutics March 15, 2004; San Carlos, CA and New York, NY — ChemoCentryx, Inc., a privately held focused pharmaceutical company, and Forest
View HTML
Toggle Summary ChemoCentryx Announces 2011 Fourth Quarter and Full Year Financial Results
MOUNTAIN VIEW, Calif. , March 30, 2012 /PRNewswire/ -- ChemoCentryx, Inc. (NASDAQ: CCXI) announced today its financial results for the fourth quarter and year ended December 31, 2011 . Net income for the fourth quarter ended December 31, 2011 was $18.2 million compared to $5.1 million during the
View HTML
Toggle Summary ChemoCentryx Announces 2012 Fourth Quarter and Year-End Financial Results
Company Highlights 2012 Achievements and Anticipated Milestones in 2013
View HTML
Toggle Summary ChemoCentryx Announces Appointment of Health Care Insurance Executive Ira Klein, MD, to Company's Board of Directors
MOUNTAIN VIEW, Calif. , May 28, 2013 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) has announced the appointment of Ira Klein , MD, MBA, FACP, to its Board of Directors. Most recently the Chief of Staff to the Chief Medical Officer (CMO) at Aetna, Dr.
View HTML
Toggle Summary ChemoCentryx Announces Appointment of James L. Tyree to the Company's Board of Directors
MOUNTAIN VIEW, Calif. , June 7, 2012 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that James L. Tyree has been appointed to the Company's Board of Directors, effective immediately and that it has increased the size of its board from six to seven. Mr.
View HTML